News - Vertex, Merck & Co


Current filters:

VertexMerck & Co

Popular Filters

Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market


One year post launch, Vertex's (Nasdaq: VRTX) Incivek (telaprevir) and Merck & Co (NYSE: MRK) and Roche's…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek versus Victrelis in hepatitis C virus treatment: US physician views


For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians survey by advisory…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Hepatitis C drug market in Mexico expected to double to $104 million in 2015


The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice


Three months after the launch of Vertex’ Incivek (telaprevir) and Merck & Co/Roche’s Victrelis…

IncivekMarkets & MarketingMerck & CoPharmaceuticalRocheVertexVictrelis

Launch trends for Incivek and Victrelis in hepatitis C sector


Results from a survey fielded one month after the launch of Vertex’ (Nasdaq: VRTX) Incivek (telaprevir)…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalVertexVictrelis

Back to top